Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenon Pharmaceuticals Inc.XENE · Entity 2602 | Director · PRESIDENT & CEO | September 30, 2026 | October 01, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenon Pharmaceuticals Inc.
Report date September 30, 2026 · Filed October 01, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common SharesSEC Table I · non-derivative | Direct | 49,923 |
Reported balance
After 2026-09-30 transaction · row 1
1 source rowRow 1 · 2026-09-30 · Purchase · Acquired 30,000 · Balance 49,923 |
| Common SharesSEC Table I · non-derivative | IndirectBy Spouse | 14,300 |
Reported balance
Holding disclosure · report date 2026-09-30 · row 2
Holding and transaction disclosures are not merged.
1 source rowRow 2 · Balance 14,300 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 23, 2025 Filed Jan 28, 2025 01:28 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 16,217 | $17.76 | $288,013.92 |
DisclosureSEC source: 0000950170-25-009388 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,519 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 11, 2024 Filed Mar 12, 2024 22:33 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $44.37 | $0.00 |
DisclosureSEC source: 0000950170-24-030226 · ownership.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Shares · 250,000 shares Expires 2034-03-10 F1 · derivative.exercise_date: Vesting 25% on January 1, 2025, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,172 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · derivative · entry 13 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 6,172 shares Expires 2024-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F7 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 20,576 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · derivative · entry 12 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 20,576 shares Expires 2024-01-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F7 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionStock Option (Right to Buy) · Derivative | 42,592 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · derivative · entry 11 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 42,592 shares Expires 2023-07-31 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. F7 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 1,407 | $41.49 | $58,376.43 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 9 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,302 F6 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.48 to $41.52, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 1,171 | $41.84 | $48,994.64 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 8 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,709 F2 · price: Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 6,172 | $9.85 | $60,794.20 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 7 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 13,179 | $41.37 | $545,215.23 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 6 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,708 F5 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.26 to $41.47, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 3,902 | $41.84 | $163,259.68 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 5 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,887 F2 · price: Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 20,576 | $9.85 | $202,673.60 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 4 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 44,789 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The exercise price was converted from $10.78 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the Reverse Stock Split. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | SaleCommon Shares | 17,069 | $41.44 | $707,339.36 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 3 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,213 F3 · price: The "Amount" and "Price" reported in this Column 4 reflect the aggregate number and weighted-average price, respectively, of shares sold. These shares were sold in multiple transactions at prices ranging from $41.29 to $41.60, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the SEC staff, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Tax withholdingCommon Shares | 7,310 | $41.84 | $305,850.40 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,282 F2 · price: Represents the closing price of the Company's common shares on May 23, 2023 for purposes of net settlement calculations. Read SEC document |
| May 24, 2023 Filed May 26, 2023 23:10 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | Exercise / conversionCommon Shares | 42,592 | $9.44 | $402,068.48 |
DisclosureSEC source: 0000950170-23-024600 · ownership.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,592 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The exercise price was converted from $9.76 CAD using the closing rate of exchange of the Bank of Canada on the date of grant, after giving effect to the 1-for-4.86 reverse stock split of the Issuer's outstanding shares effected October 1, 2014 (the "Reverse Stock Split"). The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the date of exercise. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 20:36 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 380,000 | $0.00 Strike: $34.18 | $0.00 |
DisclosureSEC source: 0001209191-23-018482 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 380,000 Underlying: Common Shares · 380,000 shares Expires 2033-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2024 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 20:15 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 400,000 | $0.00 Strike: $30.01 | $0.00 |
DisclosureSEC source: 0001209191-22-018453 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 400,000 Underlying: Common Shares · 400,000 shares Expires 2032-03-09 F1 · derivative.exercise_date: Vesting 25% on January 1, 2023 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| June 03, 2021 Filed Jun 3, 2021 20:46 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 125,000 | $0.00 Strike: $18.56 | $0.00 |
DisclosureSEC source: 0001209191-21-037707 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · Director · PRESIDENT & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,000 Underlying: Common Shares · 125,000 shares Expires 2031-06-02 F1 · derivative.exercise_date: 25% on the first anniversary of June 3, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2021 Filed Mar 15, 2021 20:37 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $20.55 | $0.00 |
DisclosureSEC source: 0001209191-21-020476 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · PRESIDENT & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Shares · 100,000 shares Expires 2031-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2022 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2020 Filed Mar 13, 2020 21:03 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $11.58 | $0.00 |
DisclosureSEC source: 0001209191-20-018951 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · PRESIDENT & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Shares · 145,000 shares Expires 2030-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2021 and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| September 16, 2019 Filed Sep 18, 2019 22:47 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 135,000 | $0.00 Strike: $9.44 | $0.00 |
DisclosureSEC source: 0001209191-19-050143 · doc4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · PRESIDENT & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,000 Underlying: Common Shares · 135,000 shares Expires 2029-09-15 F1 · derivative.exercise_date: Vesting over 36 months, in equal amounts, on the last day of each month. Read SEC document |
| March 12, 2018 Filed Mar 13, 2018 21:42 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 105,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001171843-18-001914 · form4.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · PRESIDENT & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 105,000 Underlying: Common Shares · 105,000 shares Expires 2028-03-11 F1 · derivative.exercise_date: Vesting 25% on January 1, 2019, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| October 23, 2017 Filed Oct 24, 2017 22:48 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.10 | $0.00 |
DisclosureSEC source: 0001171843-17-006258 · form4mortimer.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Shares · 25,000 shares Expires 2027-10-22 F1 · derivative.exercise_date: Vesting 25% on October 23, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:07 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Stock | 10,000 | $2.90 | $29,000.00 |
DisclosureSEC source: 0001171843-17-005071 · f4_mortimer081417.xml · nonDerivative · entry 2 MORTIMER IAN · CIK 0001619961 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 14,300 Read SEC document |
| August 10, 2017 Filed Aug 14, 2017 22:07 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | PurchaseCommon Stock | 5,000 | $2.85 | $14,225.00 |
DisclosureSEC source: 0001171843-17-005071 · f4_mortimer081417.xml · nonDerivative · entry 1 MORTIMER IAN · CIK 0001619961 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,000 Read SEC document |
| March 13, 2017 Filed Mar 14, 2017 20:26 UTC | Xenon Pharmaceuticals Inc. XENE · Entity 2602 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $8.40 | $0.00 |
DisclosureSEC source: 0001171843-17-001506 · formfour.xml · derivative · entry 1 MORTIMER IAN · CIK 0001619961 · CFO & COO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Shares · 75,000 shares Expires 2027-03-12 F1 · derivative.exercise_date: Vesting 25% on January 1, 2018, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.